ReviewOncotarget2010
Standards and impact of hematopathology in myelodysplastic syndromes (MDS).
Review in Oncotarget, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Association between glutathione S-transferase T1 null genotype and risk of myelodysplastic syndromes: a comprehensive meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- The Impact of Microenvironment and Dysplasia Types on the Prognosis of Myelodysplastic Syndrome.Diagnostics (Basel, Switzerland) · 2024Article
- Infrared Spectroscopy: A New Frontier in Hematological Disease Diagnosis.International journal of molecular sciences · 2023Review
- Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.Cytometry. Part B, Clinical cytometry · 2023Article
- Prognostic significance of peritumoral fibrosis after resection of pancreatic head cancer.Oncology letters · 2020Article
- ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.Pathobiology : journal of immunopathology, molecular and cellular biology · 2019Review
- The underestimated role of basophils in PhEuropean journal of clinical investigation · 2018Review
- A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the "MDS thermometer".BMC hematology · 2018Article
- Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.Oncotarget · 2017Article
- TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.Oncotarget · 2017Article
- Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.Leukemia · 2017Review
- Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?Current hematologic malignancy reports · 2015Review
- Importance of classical morphology in the diagnosis of myelodysplastic syndrome.Mediterranean journal of hematology and infectious diseases · 2015Review
- [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].Der Pathologe · 2013Review
- Article
- Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis.American journal of cancer research · 2011Article
- Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis, classification, and prognostication of patients with myelodysplastic syndromes (MDS) are usually based on clinical parameters, analysis of peripheral blood and bone marrow smears, and cytogenetic determinants. However, a thorough histologic and immunohistochemical examination of the bone marrow is often required for a final diagnosis and exact classification in these patients. Notably, histology and immunohistology may reveal dysplasia in megakaryocytes or other bone marrow lineages and/or the presence of clusters of CD34-positive precursor cells. In other cases, histology may reveal an unrelated or co-existing hematopoietic neoplasm, or may support the conclusion the patient is suffering from acute myeloid leukemia rather than MDS. Moreover, histologic investigations and immunohistology may reveal an increase in tryptase-positive cells, a coexisting systemic mastocytosis, or bone marrow fibrosis, which is of prognostic significance. To discuss diagnostic algorithms, terminologies, parameters, and specific issues in the hematopathologic evaluation of MDS, a Working Conference involving a consortium of US and EU experts, was organized in June 2010. The outcomes of the conference and resulting recommendations provided by the faculty, are reported in this article. These guidelines should assist in the diagnosis, classification, and prognostication in MDS in daily practice as well as in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.